JPH058173B2 - - Google Patents
Info
- Publication number
- JPH058173B2 JPH058173B2 JP58065201A JP6520183A JPH058173B2 JP H058173 B2 JPH058173 B2 JP H058173B2 JP 58065201 A JP58065201 A JP 58065201A JP 6520183 A JP6520183 A JP 6520183A JP H058173 B2 JPH058173 B2 JP H058173B2
- Authority
- JP
- Japan
- Prior art keywords
- substance
- reaction
- hours
- boehringer
- constituent sugars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000126 substance Substances 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 235000000346 sugar Nutrition 0.000 claims description 14
- 239000000470 constituent Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 10
- 229920001282 polysaccharide Polymers 0.000 claims description 10
- 239000005017 polysaccharide Substances 0.000 claims description 10
- 150000008163 sugars Chemical class 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 230000036772 blood pressure Effects 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000000862 absorption spectrum Methods 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 229920001429 chelating resin Polymers 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 238000005199 ultracentrifugation Methods 0.000 claims description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 claims description 3
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- FNEHAOQZWPHONV-UHFFFAOYSA-N 9h-carbazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 FNEHAOQZWPHONV-UHFFFAOYSA-N 0.000 claims description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims description 2
- 229920002684 Sepharose Polymers 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 108090000637 alpha-Amylases Proteins 0.000 claims description 2
- 102000004139 alpha-Amylases Human genes 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- 102000005840 alpha-Galactosidase Human genes 0.000 claims description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 claims description 2
- 229940024171 alpha-amylase Drugs 0.000 claims description 2
- MMCPOSDMTGQNKG-UHFFFAOYSA-N anilinium chloride Chemical compound Cl.NC1=CC=CC=C1 MMCPOSDMTGQNKG-UHFFFAOYSA-N 0.000 claims description 2
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 108010019077 beta-Amylase Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 2
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 238000000354 decomposition reaction Methods 0.000 claims description 2
- 238000011033 desalting Methods 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 239000008055 phosphate buffer solution Substances 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 239000011800 void material Substances 0.000 claims description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 claims 2
- 239000000706 filtrate Substances 0.000 claims 2
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 4
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 3
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Description
本発明は、高分子多糖類物質MPS−80を有効
成分とする血圧上昇抑制剤に関するものである。
一般に、食品の構成成分の一つである多糖類
は、近年多くの疫学調査の結果から、大腸がん、
動脈硬化性疾患など多くの発病予防に重要な役割
を果していることが明らかとなつてきた。中で
も、血中コレステロール上昇を抑制する作用があ
る種の多糖類に存在することが明らかになるにつ
れ、動脈硬化性疾患の予防と治療の面から注目さ
れるようになつた。
先に、各種乳酸菌から新規高分子多糖類物質
MPS−80(特願昭56−3039)を見出すに至り、
MPS−80がすぐれた高分子多糖類であるところ
から、血圧上昇抑制作用を有するかどうか鋭意研
究したところ、MPS−80にかなりの血圧上昇抑
制作用が認められ、本発明を完成するに至つた。
本発明においては、MPS−80を経口投与剤と
して投与を続ければ、動脈硬化性疾患や高血圧疾
患の治療ならびに予防に効果的である。投与量と
しては、MPS−800.1〜10g/Kg/日程度である。
次にMPS−80について説明する。
MPS−80はLactobacillus jugurti No.851、
FERM BP−66又はStreptococcus
thermophilus No.127、FERM BP−65によつて
生産される。
MPS−80の理化学的性質は次の通りである。
(1) 元素分析
C:42.2%
H: 6.9%
O:50.4%
(2) 分子量
(i) 限外過法による場合。
Sepharose 2Bによる限外過を行なつた結果
を第1図に示した。
カラムサイズ2.5×40.5cm;フラクシヨン5g;
試料2.5mg(1ml)を負荷;展開剤0.05Mりん酸
緩衝液(PH6.0);の条件により、本物質はほぼ
Void Volume付近に分画される。
(ii) 超遠心法による場合。
0.2Mりん酸緩衝液(PH7.3)に0.1%濃度で溶解
した試料について超遠心法(設定回転数
51200RPM)により沈降定数を求めたところ
7.98S(S:Svedberg単位)であつた。(沈降は単
一状態を示した。)
(3) 融点(分解点)
本物質は262℃付近で変色が始まり、263〜264
℃で黒変する。
(4) 比旋光度
〔a〕18 D=+33.2(C=0.5%)
(5) 紫外部吸収スペクトル
第2図に示す通りである。
(6) 赤外部吸収スペクトル
第3図に示す通りである。
(7) 溶剤に対する溶解性
水に可溶、メタノール、エタノール、アセト
ン、エーテルに不溶。
(8) 呈色反応
(i) モーリツシユ反応 +
(ii) アンスロン反応 +
(iii) システイン−硫酸反応 +
(iv) アニリン−塩酸反応 −
(v) カルバゾール−硫酸反応 −
(vi) エルソン−モルガン反応 −
(vii) ビユレツト反応 −
(9) 塩基性、酸性、中性の別
本物質の0.1%〜0.5%水溶液のPHは中性であ
る。
(10) 物質の色
本物質の凍結乾燥物は白色繊維状である。
(11) 構成糖の種類
5%SE−52(2mカラム)を使用し、GLCによ
る構成糖の種類を調べた。
条件:昇温150℃〜230℃(3℃/min)試料を
2N−H2SO4で沸とう水中4時間加水分解し、炭
酸バリウムで中和後過した。
液についてアンバーライトIRA−410および
アンバーライトIR−120Bで脱塩後濃縮乾固し、
TMS化してGLCにかけた。その結果、本物質の
構成糖としてグルコース、ガラクトースが認めら
れた。
(12) 構成糖の組成比
試料を2N−H2SO4で沸とう水中4時間加水分
解し、炭酸バリウムで中和後過し、その液に
ついて酵素法により構成糖の組成比を調べた。そ
の結果グルコース:ガラクトース=2.2〜1.9:1
であつた。
(13) C13−NMRスペクトル(D2O中、TMS基
準)(ppm)
第4図に結果を示した。
(14) 酵素による分解性
0.05M酢酸緩衝液に溶解した本物質について各
種酵素を作用させた。酵素による分解性はソモギ
ー・ネルソン法による還元糖量の増加で判定し
た。
使用した酵素と反応条件。
a α−Amylase(ベーリンガー社)PH5.9、37
℃、4時間
b β−Amylase(ベーリンガー社)PH4.8、30
℃、4時間
c β−Galactosidase(ベーリンガー社)PH4.8、
30℃、4時間
d Amyloglucosidase(ベーリンガー社)PH4.8、
30℃、4時間
e α−Galactosidase(ベーリンガー社)PH4.8、
30℃、4時間
上記条件下ではa〜eすべてにおいて、還元糖
量の増加は全く認められなかつた。
(15) LD50
ddY5w♀マウス(平均体重21.3g、1群7匹)
を用い、生理食塩水に溶解した試料を各種投与量
で腹腔内に1回投与して10日間観察しLD50を求
めた。その結果、LD50は200mg/Kg体重以上であ
つた。
次に本発明の製造例、実施例を示す。
製造例
ホエー培地(10%w/vホエー粉+0.5%w/
vビール酵母エキス)10にLactobacillus
Jugurti No.851、FERM BP−66を接種し、37℃
で24時間静置培養し、培養終了後、遠心分離
(10000rpm、15min)にて培養上澄液9.2を得
る。この上澄液に99.5%エチルアルコールを最終
濃度として35%(v/v)となるように添加す
る。本操作により沈澱物質が認められるようにな
り、この沈澱物質を遠心分離(10000rpm、
5min)し、沈澱物質1.2gを得る。
この沈澱物質にイオン交換水を加え溶解後、不
溶性物質を遠心分離(10000rpm、15min)にて
除去する。エチルアルコール添加による沈澱物質
の回収と水洗の操作を計3回繰り返すことにより
800mgの粗精製物が得られる。
ここに得られた粗精製物を0.05Mりん酸緩衝液
(PH6.0)に溶解し、同緩衝液で十分に緩衝化した
ジエチルアミノエチルセルロース(DEAE−セル
ロース)を充填したカラムに負荷する。同緩衝液
を流し、DEAE−セルロースに非吸着性物質を含
む通過液を採取する。非吸着性物質を含む溶液を
凍結乾燥した後、イオン交換水に溶解し、イオン
交換水に対して10℃で4日間、透析チユーブにて
透析を行なう。透析終了後、透析内液を凍結乾燥
し、高分子多糖類物質MPS−80の凍結乾燥標品
500mgを得る。
実施例
製造例で得られた培養液をそのままアルコール
沈澱させて得られた粗物質(MPS−80を3%
含有する)を市販のラツト、マウス繁殖用飼料に
10%添加混合した。これを飼料とする。
対照として、飼料と同じたん白質含量と、エ
ネルギーを揃えるためにホエー蛋白質を同じ市販
のラツト、マウス繁殖用飼料に10%添加混合し
た。これを飼料とする。動物として、離乳直後
の体重40〜50gの高血圧自然発症ラツト(SHR)
雄を用いた。このSHRは、一般の繁殖用飼料で
飼育されると血圧は、正常なラツトに比較して著
しく上昇してくる性質を有しているものである。
実験区は、SHRを30匹飼料にて飼育した。
実験区は同じく、SHRを30匹飼料にて飼育
した。両実験区共に、毎週ラツトの尾動脈の変化
から血圧を測定した。実験結果は表1に示され、
これをグラフに示したのが第5図である。
表1及び第5図から明らかなように、飼料開始
後、実験区の方が絶えず実験区よりも血圧が
低かつたことが分る。
The present invention relates to an antihypertensive agent containing a high-molecular-weight polysaccharide substance MPS-80 as an active ingredient. In general, polysaccharides, which are one of the constituents of food, have been shown to cause colorectal cancer and cancer, based on the results of many epidemiological studies in recent years.
It has become clear that they play an important role in preventing the onset of many diseases such as arteriosclerotic diseases. In particular, as it became clear that certain polysaccharides have the effect of suppressing the rise in blood cholesterol, they have attracted attention from the perspective of prevention and treatment of arteriosclerotic diseases. First, a new polymeric polysaccharide substance was extracted from various lactic acid bacteria.
I came across MPS-80 (patent application 1983-3039),
Since MPS-80 is an excellent polymeric polysaccharide, we conducted extensive research to determine whether it has an effect of suppressing blood pressure rise.We found that MPS-80 has a significant effect of suppressing blood pressure rise, which led us to complete the present invention. . In the present invention, if MPS-80 is continuously administered as an orally administered agent, it is effective in treating and preventing arteriosclerotic diseases and hypertensive diseases. The dosage is approximately MPS-800.1 to 10g/Kg/day. Next, the MPS-80 will be explained. MPS−80 is Lactobacillus jugurti No.851,
FERM BP−66 or Streptococcus
thermophilus No. 127, produced by FERM BP-65. The physical and chemical properties of MPS-80 are as follows. (1) Elemental analysis C: 42.2% H: 6.9% O: 50.4% (2) Molecular weight (i) By ultrafiltration method. The results of ultraviolet analysis using Sepharose 2B are shown in Figure 1. Column size 2.5×40.5cm; fraction 5g;
Loading 2.5 mg (1 ml) of sample; 0.05 M phosphate buffer solution (PH6.0) as developing agent;
It is fractionated near Void Volume. (ii) By ultracentrifugation. A sample dissolved in 0.2M phosphate buffer (PH7.3) at a concentration of 0.1% was subjected to ultracentrifugation (set rotation speed).
51200RPM) to determine the sedimentation constant.
It was 7.98S (S: Svedberg unit). (Sedimentation showed a single state.) (3) Melting point (decomposition point) This substance begins to change color at around 262℃, and reaches 263-264℃.
It turns black at ℃. (4) Specific rotation [a] 18 D = +33.2 (C = 0.5%) (5) Ultraviolet absorption spectrum As shown in Figure 2. (6) Infrared absorption spectrum As shown in Figure 3. (7) Solubility in solvents Soluble in water, insoluble in methanol, ethanol, acetone, and ether. (8) Color reaction (i) Moritsch reaction + (ii) Anthrone reaction + (iii) Cysteine-sulfuric acid reaction + (iv) Aniline-hydrochloric acid reaction − (v) Carbazole-sulfuric acid reaction − (vi) Elson-Morgan reaction − (vii) Billetz reaction - (9) Basic, acidic, neutral The pH of a 0.1% to 0.5% aqueous solution of this substance is neutral. (10) Color of substance The lyophilized product of this substance is white fibrous. (11) Types of constituent sugars The types of constituent sugars were investigated by GLC using 5% SE-52 (2m column). Conditions: Temperature increase from 150℃ to 230℃ (3℃/min)
It was hydrolyzed in boiling water with 2N-H 2 SO 4 for 4 hours, neutralized with barium carbonate, and filtered. After desalting the liquid with Amberlite IRA-410 and Amberlite IR-120B, it was concentrated to dryness.
It was converted into TMS and subjected to GLC. As a result, glucose and galactose were recognized as constituent sugars of this substance. (12) Composition ratio of constituent sugars A sample was hydrolyzed in boiling water with 2N-H 2 SO 4 for 4 hours, neutralized with barium carbonate, filtered, and the composition ratio of constituent sugars was investigated using the enzyme method. As a result, glucose:galactose=2.2-1.9:1
It was hot. (13) C 13 -NMR spectrum (in D 2 O, TMS standard) (ppm) The results are shown in FIG. (14) Degradability by enzymes Various enzymes were allowed to act on this substance dissolved in 0.05M acetate buffer. Enzymatic degradability was determined by the increase in reducing sugar amount using the Somogyi-Nelson method. Enzymes and reaction conditions used. a α-Amylase (Boehringer) PH5.9, 37
°C, 4 hoursb β-Amylase (Boehringer) PH4.8, 30
°C, 4 hours c β-Galactosidase (Boehringer) PH4.8,
30℃, 4 hours d Amyloglucosidase (Boehringer) PH4.8,
30℃, 4 hours e α-Galactosidase (Boehringer) PH4.8,
30°C, 4 hours Under the above conditions, no increase in reducing sugar content was observed in all cases a to e. (15) LD 50 ddY5w♀ mice (average weight 21.3g, 7 mice per group)
Using this method, various doses of samples dissolved in physiological saline were intraperitoneally administered once, observed for 10 days, and the LD 50 was determined. As a result, the LD 50 was 200 mg/Kg body weight or more. Next, production examples and examples of the present invention will be shown. Production example Whey medium (10% w/v whey powder + 0.5% w/
v beer yeast extract) Lactobacillus in 10
Jugurti No.851, inoculated with FERM BP−66, 37℃
After culture is completed, culture supernatant 9.2 is obtained by centrifugation (10,000 rpm, 15 min). To this supernatant, 99.5% ethyl alcohol is added to a final concentration of 35% (v/v). As a result of this operation, precipitated substances can be observed, and these precipitated substances are centrifuged (10,000 rpm,
5 min) to obtain 1.2 g of precipitated material. After dissolving the precipitated material by adding ion-exchanged water, insoluble materials are removed by centrifugation (10,000 rpm, 15 min). By repeating the operation of collecting precipitated substances by adding ethyl alcohol and washing with water three times in total.
800 mg of crude product is obtained. The crude product obtained here is dissolved in 0.05M phosphate buffer (PH6.0) and loaded onto a column packed with diethylaminoethylcellulose (DEAE-cellulose) sufficiently buffered with the same buffer. The same buffer solution is passed through, and the flow-through solution containing substances not adsorbed to DEAE-cellulose is collected. After the solution containing the non-adsorbable substance is freeze-dried, it is dissolved in ion-exchanged water and dialyzed against ion-exchanged water at 10° C. for 4 days in a dialysis tube. After dialysis, the dialysis fluid is freeze-dried and a freeze-dried specimen of the polymeric polysaccharide substance MPS-80 is prepared.
Get 500mg. Example Crude material obtained by alcohol precipitation of the culture solution obtained in the production example (3% MPS-80)
containing) in commercially available rat and mouse breeding feed.
10% was added and mixed. This is used as feed. As a control, 10% whey protein was added to the same commercially available rat and mouse breeding feed to match the protein content and energy levels of the feed. This is used as feed. As animals, spontaneously hypertensive rats (SHR) weighing 40 to 50 g immediately after weaning.
Males were used. This SHR has the property that when raised on general breeding feed, its blood pressure increases significantly compared to normal rats. In the experimental area, 30 SHRs were raised on feed.
In the same experimental area, 30 SHRs were fed with feed. In both experimental groups, blood pressure was measured weekly from changes in the rat's tail artery. The experimental results are shown in Table 1,
FIG. 5 shows this in a graph. As is clear from Table 1 and FIG. 5, blood pressure in the experimental group was consistently lower than in the experimental group after the start of feeding.
【表】【table】
第1図は高分子多糖類物質MPS−80の限外
過による展開図である。a……高分子多糖類物質
MPS−80、b……Blue Dextran 第2図は高分
子多糖類物質MPS−80の紫外部吸収スペクトル
を、第3図は同じく赤外部吸収スペクトルを、第
4図は同じくC13−NMRスペクトルを示す図で
ある。第5図は実施例において高血圧自然発症ラ
ツトを用い血圧上昇を比較試験した図である。
FIG. 1 is a development diagram of the polymeric polysaccharide substance MPS-80 obtained by ultrafiltration. a...High molecular weight polysaccharide substance
MPS-80, b...Blue Dextran Figure 2 shows the ultraviolet absorption spectrum of the polymeric polysaccharide substance MPS-80, Figure 3 shows the same infrared absorption spectrum, and Figure 4 shows the same C 13 -NMR spectrum. FIG. FIG. 5 is a diagram showing a comparative test of blood pressure increase using spontaneously hypertensive rats in Examples.
Claims (1)
MPS−80を有効成分とする血圧上昇抑制剤。 (1) 元素分子 C:42.2% H:6.9% O:50.4% (2) 分子量 (i) 限外濾過法による場合。 Sepharose 2Bによる限外濾過を行なつた結果
を第1図に示した。 カラムサイズ2.5×40.5cm;フラクシヨン5g;
試料2.5mg(1ml)を負荷;展開剤0.05Mりん酸
緩衝液(PH6.0);の条件により、本物質はほぼ
Void Volume付近に分画される。 (ii) 超遠心法による場合。 0.2Mりん酸緩衝液(PH7.3)に0.1%濃度で溶解
した試料について超遠心法(設定回転数
51200RPM)により沈降定数を求めたところ
7.98S(S:Svedberg単位)であつた。 (沈降は単一状態を示した。) (3) 融点(分解点) 本物質は262℃付近で変色が始まり、263〜264
℃で黒変する。 (4) 比旋光度 〔a〕18 D=+33.2(C=0.5%) (5) 紫外部吸収スペクトル 第2図に示す通りである。 (6) 赤外部吸収スペクトル 第3図に示す通りである。 (7) 溶剤に対する溶解性 水に可溶、メタノール、エタノール、アセト
ン、エーテルに不溶。 (8) 呈色反応 (i) モーリツシユ反応 + (ii) アンスロン反応 + (iii) システイン−硫酸反応 + (iv) アニリン−塩酸反応 − (v) カルバゾール−硫酸反応 − (vi) エルソン−モルガン反応 − (vii) ビユレツト反応 − (9) 塩基性、酸性、中性の別 本物質の0.1%〜0.5%水溶液のPHは中性であ
る。 (10) 物質の色 本物質の凍結乾燥物は白色繊維状である。 (11) 構成糖の種類 5%SE−52(2mカラム)を使用し、GLCによ
る構成糖の種類を調べた。 条件:昇温150℃〜230℃(3℃/min)試料を
2N−H2SO4で沸とう水中4時間加水分解し、炭
酸バリウムで中和後濾過した。 濾液についてアンバーライトIRA−410および
アンバーライトIR−120Bで脱塩後、濃縮乾固し、
TMS化してGLCにかけた。その結果、本物質の
構成糖としてグルコース、ガラクトースが認めら
れた。 (12) 構成糖の組成比 試料を2N−H2SO4で沸とう水中4時間加水分
解し、炭酸バリウムで中和後濾過し、その濾液に
ついて酵素法により構成糖の組成比を調べた。そ
の結果、グルコース:ガラクトース=2.2〜1.9:
1であつた。 (13) C13−NMRスペクトル(D2O中、TMS基
準)(ppm) 第4図に結果を示した。 (14) 酵素による分解性 0.05M酢酸緩衝液に溶解した本物質について、
各種酵素を作用させた。酵素による分解性はソモ
ギー・ネルソン法による還元糖量の増加で判定し
た。 使用した酵素と反応条件。 a α−Amylase(ベーリンガー社)PH5.9、37
℃、4時間 b β−Amylase(ベーリンガー社)PH4.8、30
℃、4時間 c β−Galactosidase(ベーリンガー社)PH4.8、
30℃、4時間 d Amyloglucosidase(ベーリンガー社)PH4.8、
30℃、4時間 e α−Galactosidase(ベーリンガー社)PH4.8、
30℃、4時間 上記条件下ではa〜eすべてにおいて、還元糖
量の増加は全く認められなかつた。 (15) LD50 ddY5w♀マウス(平均体重21.3g、1群7匹)
を用い、生理食塩水に溶解した試料を各種投与量
で腹腔内に1回投与して10日間観察しLD50を求
めた。その結果、LD50は200mg/Kg体重以上であ
つた。[Claims] 1. A polymeric polysaccharide substance having the following physical and chemical properties:
A blood pressure increase suppressant containing MPS-80 as an active ingredient. (1) Elemental molecules C: 42.2% H: 6.9% O: 50.4% (2) Molecular weight (i) When using ultrafiltration method. The results of ultrafiltration using Sepharose 2B are shown in FIG. Column size 2.5×40.5cm; fraction 5g;
Loading 2.5 mg (1 ml) of sample; 0.05 M phosphate buffer solution (PH6.0) as developing agent;
It is fractionated near Void Volume. (ii) By ultracentrifugation. A sample dissolved in 0.2M phosphate buffer (PH7.3) at a concentration of 0.1% was subjected to ultracentrifugation (set rotation speed).
51200RPM) to determine the sedimentation constant.
It was 7.98S (S: Svedberg unit). (Sedimentation showed a single state.) (3) Melting point (decomposition point) This substance begins to change color at around 262℃, and reaches 263-264℃.
It turns black at ℃. (4) Specific rotation [a] 18 D = +33.2 (C = 0.5%) (5) Ultraviolet absorption spectrum As shown in Figure 2. (6) Infrared absorption spectrum As shown in Figure 3. (7) Solubility in solvents Soluble in water, insoluble in methanol, ethanol, acetone, and ether. (8) Color reaction (i) Moritsch reaction + (ii) Anthrone reaction + (iii) Cysteine-sulfuric acid reaction + (iv) Aniline-hydrochloric acid reaction − (v) Carbazole-sulfuric acid reaction − (vi) Elson-Morgan reaction − (vii) Billetz reaction - (9) Basic, acidic, neutral The pH of a 0.1% to 0.5% aqueous solution of this substance is neutral. (10) Color of substance The lyophilized product of this substance is white fibrous. (11) Types of constituent sugars The types of constituent sugars were investigated by GLC using 5% SE-52 (2m column). Conditions: Temperature increase from 150℃ to 230℃ (3℃/min)
The mixture was hydrolyzed in boiling water with 2N-H 2 SO 4 for 4 hours, neutralized with barium carbonate, and then filtered. After desalting the filtrate with Amberlite IRA-410 and Amberlite IR-120B, it was concentrated to dryness.
It was converted into TMS and subjected to GLC. As a result, glucose and galactose were recognized as constituent sugars of this substance. (12) Compositional ratio of constituent sugars A sample was hydrolyzed in boiling water with 2N-H 2 SO 4 for 4 hours, neutralized with barium carbonate and filtered, and the filtrate was examined for the compositional ratio of constituent sugars by an enzymatic method. As a result, glucose: galactose = 2.2-1.9:
It was 1. (13) C 13 -NMR spectrum (in D 2 O, TMS standard) (ppm) The results are shown in FIG. (14) Degradability by enzymes Regarding this substance dissolved in 0.05M acetate buffer,
Various enzymes were applied. Enzymatic degradability was determined by the increase in reducing sugar amount using the Somogyi-Nelson method. Enzymes and reaction conditions used. a α-Amylase (Boehringer) PH5.9, 37
°C, 4 hoursb β-Amylase (Boehringer) PH4.8, 30
°C, 4 hours c β-Galactosidase (Boehringer) PH4.8,
30℃, 4 hours d Amyloglucosidase (Boehringer) PH4.8,
30℃, 4 hours e α-Galactosidase (Boehringer) PH4.8,
30°C, 4 hours Under the above conditions, no increase in reducing sugar content was observed in all cases a to e. (15) LD 50 ddY5w♀ mice (average weight 21.3g, 7 mice per group)
Using this method, various doses of samples dissolved in physiological saline were intraperitoneally administered once, observed for 10 days, and the LD 50 was determined. As a result, the LD 50 was 200 mg/Kg body weight or more.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58065201A JPS59190920A (en) | 1983-04-15 | 1983-04-15 | Inhibitor against rise in blood pressure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58065201A JPS59190920A (en) | 1983-04-15 | 1983-04-15 | Inhibitor against rise in blood pressure |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS59190920A JPS59190920A (en) | 1984-10-29 |
JPH058173B2 true JPH058173B2 (en) | 1993-02-01 |
Family
ID=13280059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58065201A Granted JPS59190920A (en) | 1983-04-15 | 1983-04-15 | Inhibitor against rise in blood pressure |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS59190920A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02295931A (en) * | 1989-05-09 | 1990-12-06 | Yakult Honsha Co Ltd | Extract of cell with water having antihypertensive action and antihypertensive agent |
-
1983
- 1983-04-15 JP JP58065201A patent/JPS59190920A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS59190920A (en) | 1984-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meyer | The chemistry of glycogen | |
Beer et al. | Extraction of Oat Gum from Oat Bran: Effects of Process on Yield, Molecular Weight Distribution, Viscosity and (1--> 3)(1--> 4)-b-D-Glucan Content of the Gum | |
EP1369432B2 (en) | Soluble highly branched glucose polymers and process for their preparation | |
US3973008A (en) | Konjac mannan | |
JPH0728694B2 (en) | Food composition having intestinal regulating action | |
US3928135A (en) | Process for the production of glucose polymers | |
US4396763A (en) | High molecular polysaccharide MPS-80 | |
US5939309A (en) | Bifidobacterium bifidum proliferation promoting composition containing xylooligosaccharide | |
JPH0532371B2 (en) | ||
JPH05246860A (en) | Preventive of large intestine cancer | |
CN112691115A (en) | Arabinoxylan and compound for preventing/treating gastrointestinal mucosa and liver injury | |
JPH058173B2 (en) | ||
JP2928335B2 (en) | Antihypertensives and foods and beverages | |
US5789579A (en) | Acidic polysaccharide | |
JPH0940566A (en) | Treating agent for diabetic and immunopotentiator produced from lactobacillus fermentation product | |
JP2747206B2 (en) | Composition for improving hyperglycemia | |
JPH0723315B2 (en) | Blood sugar elevation inhibitor | |
Sloven et al. | Hydrolysis and absorption of glucose polymers from rice compared with corn in chronic diarrhea of infancy | |
JPH06247861A (en) | Antiulcer agent and its production | |
JP3191956B2 (en) | Alcoholic fatty liver inhibitors | |
US4473556A (en) | Composition and method for treating gastrointestinal disturbances in animals and method for producing this composition | |
JPS6359679B2 (en) | ||
JPH06116156A (en) | Hypoglycemic agent | |
WO1985003230A1 (en) | Drug for phenylketonuria | |
CN115414398B (en) | Chestnut extract, preparation method thereof and application thereof in hypoglycemic products |